What are the recent trends in market size and growth for the arthralgia market?
The arthralgia market size has grown strongly in recent years. It will grow from $5.20 billion in 2024 to $5.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to the increasing prevalence of autoimmune diseases, rising incidence of several associated risk factors, increasing obesity, increasing prevalence of arthralgia, and increasing prevalence of joint disorders.
The arthralgia market size is expected to see strong growth in the next few years. It will grow to $7.73 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to growing awareness of arthralgia, rising geriatric population, rising healthcare infrastructure, growing demand for minimally invasive treatments, and rising prevalence of sports injuries. Major trends in the forecast period include the integration of digital health solutions, novel therapies, cell therapies, advancements in medical technology, and investment in research and development.
Get Your Free Sample of The Global Arthralgia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21104&type=smp
How have varous drivers impacted the growth of the arthralgia market?
The increasing number of cases of rheumatoid arthritis is expected to propel the growth of the arthralgia market going forward. Rheumatoid arthritis is a chronic autoimmune disorder that primarily affects joints, causing inflammation, pain, and potential joint damage. The rising number of rheumatoid arthritis cases is attributed to aging populations, genetic predisposition, lifestyle changes, and environmental factors like smoking and pollution. Rheumatoid arthritis (RA) causes arthralgia by triggering chronic inflammation in the joints, leading to pain, stiffness, and progressive damage. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, by 2040, arthritis cases in Australia are expected to rise to 5.39 million from 4.11 million in 2025, with osteoarthritis increasing to 3.11 million from 2.35 million and rheumatoid arthritis reaching 748,721. Therefore, the increasing number of cases of rheumatoid arthritis is driving the growth of the arthralgia market.
What are the primary segments of the arthralgia market?
The arthralgia market covered in this report is segmented –
1) By Cause: Osteoarthritis, Rheumatoid Arthritis, Gout, Psoriatic Arthritis, Lupus, Injuries, Infections, Other Causes
2) By Treatment Type: Medications, Therapies, Surgical Interventions, Lifestyle And Home Remedies
3) By Route Of Administration: Oral, Injectable, Topical, Transdermal
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospital, Clinics, Homecare Settings, Rehabilitation Centers
Subsegments:
1) By Osteoarthritis: Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Spine Osteoarthritis, Shoulder Osteoarthritis
2) By Rheumatoid Arthritis: Seropositive Rheumatoid Arthritis, Seronegative Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Early-Onset Rheumatoid Arthritis
3) By Gout: Primary Gout, Secondary Gout, Gouty Arthritis
4) By Psoriatic Arthritis: Symmetric Psoriatic Arthritis, Asymmetric Psoriatic Arthritis, Psoriatic Spondylitis, Distal Interphalangeal Predominant Psoriatic Arthritis
5) By Lupus: Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus, Drug-induced Lupus, Neonatal Lupus
6) By Injuries: Sports-related Injuries, Trauma and Fractures, Sprains and Strains, Tendon or Ligament Damage
7) By Infections: Septic Arthritis, Viral Arthritis, Bacterial Infections, Fungal Infections
8) By Other Causes: Fibromyalgia, Overuse Injuries, Sarcoidosis, Ankylosing Spondylitis, Crystal-induced Arthritis
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/arthralgia-global-market-report
Which firms are leading the arthralgia market?
Major companies operating in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation, Vitazan Herbs and Vitamins Inc.
How will industry trends affect the trajectory of the arthralgia market?
Major companies operating in the arthralgia market are focusing on developing innovative therapies, such as RMAT-designated gene therapy, to provide patients with advanced treatments that offer long-term pain relief and improved joint function. RMAT-designated gene therapy refers to a treatment that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which expedites the development and review of innovative gene therapies for serious or life-threatening conditions. For instance, in March 2024, Pacira BioSciences Inc., a US-based pharmaceutical company, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation for its product PCRX-201 (enekinragene inzadenovec) by the U.S. Food and Drug Administration (FDA). It is an innovative, intra-articular gene therapy candidate utilizing a helper-dependent adenovirus (HDAd) to treat knee osteoarthritis. The therapy is designed to produce interleukin-1 receptor antagonists (IL-1Ra). Pacira expressed pride in receiving the FDA’s first-ever RMAT designation for a gene therapy targeting osteoarthritis and emphasized the promising preliminary clinical results that suggest PCRX-201 may be a potential disease-modifying treatment.
Which geographic trends are shaping the arthralgia market, and which region has the highest market share?
North America was the largest region in the arthralgia market in 2024. The regions covered in the arthralgia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Arthralgia Market Report 2025 Offer?
The arthralgia market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Arthralgia refers to pain in one or more joints, often without inflammation, and can result from various causes such as infections, autoimmune diseases, or injury. It is a symptom rather than a condition, typically indicating an underlying health issue affecting the joints.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21104
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
